Navigation Links
Penn researchers identify potential target for breast cancer therapy
Date:12/22/2010

PHILADELPHIA Overexpression or hyperactivation of ErbB cell-surface receptors drives the growth of many breast cancers. Drugs, like Herceptin, that block the receptors' signals halt tumor progression in some patients. However, not all patients' tumors respond, with some becoming resistant over time. Different drugs that interfere with other steps in the signaling pathway may improve the response of patients, yet little is known about these molecules.

Now, Marcelo G. Kazanietz, PhD, professor of Pharmacology at the University of Pennsylvania School of Medicine and colleagues, report that a protein called P-Rex1 is crucial for signal transmission from ErbB receptors. What's more, they found that P-Rex1 is overexpressed in nearly 60 percent of breast cancer samples tested and patients whose tumors express P-Rex1 were more likely to develop metastasis, compared with those whose tumors did not express P-Rex1.

"We identified a downstream target of the ErbB receptors which seems to be crucial for cancer cell proliferation, migration, and metastasis," Kazanietz says. "Understanding how this pathway works should allow us to find new drugs or therapeutic approaches in the future."

The team's research is featured on the cover of the December 22 issue of Molecular Cell.

A Well-Known Family

The ErbB family of receptors is well known in the cancer world. The family includes the epidermal growth factor receptor (EGFR, also known as ErbB1); ErbB2 (also known as HER2/neu), which is the target of Herceptin; as well as ErbB and ErbB4.

Previous work from Kazanietz and others suggested the receptors might rely on small proteins in the Rac pathway to help transmit their signal. To find out if that was the case, Kazanietz and colleagues examined human breast cancer cell lines and found that one Rac pathway protein, P-Rex1, is overexpressed in numerous cell lines compared with normal mammary cells. The team also fo
'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. Researchers Turn White Fat to Energy-Burning Brown Fat in Mice
2. Finnish researchers find a compound that prevents the growth of prostate cancer cells
3. Ben-Gurion U. researchers: High resistance rates among acute otitis media pathogens in children
4. Breast inflammation is key to cancer growth, Kimmel Cancer Center researchers say
5. Researchers discover new signaling pathway linked to inflammatory disease
6. UCI researchers find novel memory-enhancing mechanism in brain
7. Researchers make critical leukemia stem cell discovery
8. U-M researchers discover way to block neurodegeneration in an adult form of Fragile X syndrome
9. Leibniz Prize 2011: 10 researchers awarded €2.5 million ($3.3 million) each
10. Researchers Turn Stem Cells Into Intestinal Tissue in Lab
11. Expert analysis of HER2 tests reveals issues with reliability, Mayo Clinic researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Penn researchers identify potential target for breast cancer therapy
(Date:11/23/2014)... 2014 The clinical trial report, ... data on the Aspergillosis clinical trial scenario. This ... the clinical trials on Aspergillosis. It includes an ... status as per the site of trial conduction ... coverage of disease clinical trials by their phase, ...
(Date:11/23/2014)... Tbdress.com has recently announced that its Special ... 2014. The special offer will provide ladies many gorgeous shoes ... the world’s largest women’s dresses retailers, and its shoes include ... great discounts on that day: Everything at Tbdress.com is up ... above $89). , People can use the following coupon codes ...
(Date:11/23/2014)... SUNDAY, Nov. 23, 2014 (HealthDay News) -- The holidays ... autism because sensory overload can trigger major meltdowns, an ... under the best of circumstances, but when you have ... Varleisha Gibbs, an occupational therapy professor at University of ... release. "It,s best to let your hosts or ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers ... has announced its new collection of power suppliers. Additionally, ... quality power suppliers. All the new models come with ... lasts until Dec. 20, 2014. , SWAccessControl.com has thousands ... supporting it for a long time. It is very ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 “BlackVue” was ... Tech Report , which features the latest and coolest ... expert and reporter for NewsWatch, conducted the product review ... unique and powerful options in the car camera industry. ... and it can be hard to find the one ...
Breaking Medicine News(10 mins):Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Tbdress.com Special Friday Shoes Sales Online Now 2Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:A Leader in Front and Rear Facing In-Car Cameras was Featured on NewsWatch Television on October 30, 2014 2
... ... ... ... ...
... ... ... ... ...
... ... ... , ... TULSA, Okla. , Feb. 19 U.S. ...
... more fumes that are likely carcinogenic than with electric ranges ... hot stove -- make that a hot gas ... cancer. , Researchers in Norway have found that cooking with ... , But, in a report published online Feb. 17 in ...
... (P4P) programs are payment models that reward workers for ... the healthcare setting, P4P programs use a variety of ... fee differentials and bonuses. A new study ... that P4P programs appear to be effective in incentivizing ...
... ... momentum created by local communities and the NGO Tostan to end the practice by 2015 ... Dakar, Senegal (PRWEB) February ... cutting (FGC) which has seen thousands of communities in Senegal join its ranks in recent ...
Cached Medicine News:Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 2Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 3Health News:New Gallup Poll Quantifies U.S. Physician Opinions on the Scope of Defensive Medicine Practices 4Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 2Health News:Abbott Announces 10 Percent Increase in Quarterly Dividend 3Health News:Two Tulsa Pharmacies Penalized for Missing Prescription Drugs 2Health News:Two Tulsa Pharmacies Penalized for Missing Prescription Drugs 3Health News:Gas Cooking Might Up Your Cancer Risk 2Health News:Gas Cooking Might Up Your Cancer Risk 3Health News:Senegal: Total End of Female Genital Cutting Now in Sight 2
(Date:11/24/2014)... , Nov. 24, 2014 The Female Health ... an investor conference call to discuss its operating results ... 30, 2014 on Tuesday, December 2, 2014 at 11:00 ... report its operating results earlier the same day. ... the conference call by dialing 1-877-374-8416 (international participants dial ...
(Date:11/24/2014)... Nov. 24, 2014  GlySens Incorporated announced today that ... grant from the National Institute of Diabetes and Digestive ... Institutes of Health (NIH).  The grant is intended to ... ICGM™ long term implantable glucose monitoring system.  Final preparations ... is expected to begin before the end of 2014. ...
(Date:11/24/2014)... DEVON, England , Nov. 24, 2014 /PRNewswire/ ... https://www.facebook.com/PifflersUnited announced the release of results ... pain therapy device, in the self-management of fibromyalgia ... the area of worst pain, very significant clinically ... The 140 group members with fibromyalgia used ...
Breaking Medicine Technology:The Female Health Company To Report FY2014 Operating Results on Tuesday, December 2, 2014 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3
... today that eleven presentations or publications on pre-clinical and ... several major tumor types will be made during the ... May 29-June 2, in Orlando, Florida. Abstracts are ... http://www.newscom.com/cgi-bin/prnh/20090227/PH75873LOGO ) Prostate Cancer ...
... (LSE: SHP, Nasdaq: SHPGY ), the global specialty ... of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII with the ... X 2), did not alter the median time it took ... reached in the subjects evaluated. In the same study, ...
Cached Medicine Technology:Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000) ...
Medicine Products: